Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 5-9 in Boston, Massachusetts.
Abstract information is as follows:
Title: A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity
Presenter: Dr. Andrew Brenner, on behalf of all the authors/investigators
Session ID: Poster Session A
Session Title: Clinical Trials
Session Date: Friday, November 6, 2015
Session Time: 12:15 PM – 3:15 PM local time
Location: Exhibit Hall C-D
Permanent Abstract Number:Â Â A54
Title: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
Session ID: Poster Session B
Session Title: Biomarkers
Session Date: Saturday, November 7, 2015
Session Time: 12:30 PM – 3:30 PM local time
Location: Exhibit Hall C-D
Permanent Abstract Number:Â Â B13
Title: FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
Session ID: Poster Session C
Session Title: Therapeutic Agents: Other
Session Date: Sunday, November 8, 2015
Session Time: 12:30 PM – 3:30 PM local time
Location: Exhibit Hall C-D
Permanent Abstract Number:Â Â C175
About 3-V Biosciences
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology based on expertise in lipid biology. The company’s lead oncology product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. Together with a group of world-renowned experts in lipid biology, we have established expertise to translate this biology into patient benefit with a focus on oncology drug development. The company is located in Menlo Park, California.
Investor Relations Contact:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 5
jjones@bplifescience.com
